Purpose Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease that
imposes a major burden on patients and healthcare systems. Three structured literature …

Over the past few years, a number of studies have revealed that a significant number of men
with prostate cancer had genetic defects in the DNA damage repair gene response and …

The availability of protein measurements and whole exome sequence data in the UK
Biobank enables investigation of potential observational and genetic protein-cancer risk …

After recent approvals, poly-adenosine diphosphate [ADP]-ribose polymerase inhibitors
(PARPis) have emerged as a frontline treatment for metastatic castration-resistant prostate …

Materials and methods This retrospective study included 23,225 patients who underwent
prostate MRI between 2017 and 2022. Cancer risk factors (family history of cancer and …

This review provides a comprehensive analysis of the progress made in cancer research
within the United States. Over the past few decades, significant strides have been taken to …

Prostate cancer is heterogeneous with varied pathologic features and presents with a wide
spectrum of clinical manifestations from indolent to advanced cancer. Interrogation of the …

In the setting of mCRPC, the success of an individualized approach to treatment has varied
particularly dependent on genetics. In 2015, Robinson et al. conducted a prospective whole …

Protein products of the BRCA1 and BRCA2 genes play a key role in DNA repair processes
carried out by homologous recombination. Maintaining the correct double-stranded DNA …

Produkty białkowe genów BRCA1 i BRCA2 odgrywają kluczową rolę w procesach naprawy
DNA, realizowanych na drodze rekombinacji homologicznej. Utrzymanie prawidłowej …